The road ahead

Read more about our strategy and business idea

The latest quarterly report

Investor relations

Dicot's drug candidate LIB-01, which aims at treating erection problems and premature ejaculation, is in the preclinical development phase.

The development is taking place under own auspice until phase 2 studies. Thereafter, the intention is to enter into strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies in order to be able to introduce LIB-01 to the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,600 shareholders.

The global market for treating sexual dysfunctions is annually worth more than 50 billion SEK as the underlying causes increase and the proportion of elderly increases.

There are currently no long-lasting, effective therapeutic drugs available on the market. Today's potency drugs arrived on the market over 20 years ago and have their limitations.

30% of men with diagnosed erectile dysfunction do not respond to drugs on the market today. As LIB-01 functions in a different way, it may open the possibility for these patients to receive a treatment that works.

According to early studies, Dicot's drug candidate LIB-01 has a longer lasting duration. Unlike today's potency drugs, which must be ingested shortly before planned sexual activity.

Many men suffer from both erectile dysfunction and premature ejaculation. LIB-01 is meant to work on both symptoms, something that does not exist today.

IR contact

Göran Beijer CEO
Email: goran.beijer@dicot.se Tel: +46 706 63 60 09
Jessica Roxhed CFO
Email: jessica.roxhed@dicot.se Tel: +46 703 94 94 98